Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription


7 Ann Surg Oncol
5 Anticancer Res
1 Br J Cancer
1 Breast Cancer
8 Breast Cancer Res Treat
1 Cancer
1 Cancer Res
2 Clin Cancer Res
1 Eur J Cancer
1 Genes Chromosomes Cancer
3 Histopathology
2 J Natl Cancer Inst
1 J Surg Oncol
1 Mod Pathol
3 NPJ Breast Cancer
1 Oncol Rep
6 PLoS One
3 Radiology
1 Radiother Oncol
1 Semin Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. OBENG-GYASI S, Rose J, Dong W, Kim U, et al
    Is Medicaid Expansion Narrowing Gaps in Surgical Disparities for Low-Income Breast Cancer Patients?
    Ann Surg Oncol. 2021 Nov 27. pii: 10.1245/s10434-021-11137.
    PubMed         Abstract available

  2. BHUTIANI N, Ajkay N
    ASO Author Reflections: The Broad Impact of the Margin Consensus Guidelines for Breast-Conserving Surgery in DCIS.
    Ann Surg Oncol. 2021;28:7439-7440.

  3. KOELBEL V, Pfob A, Schaefgen B, Sinn P, et al
    ASO Visual Abstract: Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment to Reliably Exclude Residual Cancer in Breast Cancer Patients.
    Ann Surg Oncol. 2021 Nov 26. pii: 10.1245/s10434-021-10958.

  4. GUAY E, Cordeiro E, Roberts A
    Young Women with Breast Cancer: Chemotherapy or Surgery First? An Evaluation of Time to Treatment for Invasive Breast Cancer.
    Ann Surg Oncol. 2021 Nov 26. pii: 10.1245/s10434-021-11102.
    PubMed         Abstract available

  5. OBENG-GYASI S, Rose J, Koroukian S
    ASO Author Reflections: Medicaid Expansion is Key in Mitigating Surgical Disparities in Low-Income Breast Cancer Patients.
    Ann Surg Oncol. 2021 Nov 27. pii: 10.1245/s10434-021-11138.

  6. TONNESON JE, Boughey JC
    ASO Author Reflections: How COVID-19 Impacted Breast Cancer Presentation and Management.
    Ann Surg Oncol. 2021 Nov 30. pii: 10.1245/s10434-021-11098.

  7. RING A, Lang JE
    ASO Author Reflections: Advancing Circulating Tumor Cells as Liquid Biopsies to Efficiently Target Metastatic Breast Cancer.
    Ann Surg Oncol. 2021 Dec 1. pii: 10.1245/s10434-021-11139.

    Anticancer Res

  8. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed         Abstract available

  9. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed         Abstract available

  10. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed         Abstract available

  11. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed         Abstract available

  12. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed         Abstract available

    Br J Cancer

  13. CANELO-AYBAR C, Posso M, Montero N, Sola I, et al
    Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01521.
    PubMed         Abstract available

    Breast Cancer

  14. SU SY
    Nationwide mammographic screening and breast cancer mortality in Taiwan: an interrupted time-series analysis.
    Breast Cancer. 2021 Nov 26. pii: 10.1007/s12282-021-01315.
    PubMed         Abstract available

    Breast Cancer Res Treat

  15. COE F, Misra V, McCabe Y, Adderley H, et al
    Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06438.
    PubMed         Abstract available

  16. DREHER N, Matthys M, Hadeler E, Shieh Y, et al
    A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06451.
    PubMed         Abstract available

  17. DISIS ML, Cecil DL
    Breast cancer vaccines for treatment and prevention.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06459.
    PubMed         Abstract available

  18. METCALFE KA, Eisen A, Wright F, Poll A, et al
    Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06457.
    PubMed         Abstract available

  19. DINH P, Graham JD, Elder EN, Kabir M, et al
    Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06456.
    PubMed         Abstract available

  20. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, van Stam LE, et al
    The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06458.
    PubMed         Abstract available

  21. JAZIEH K, Baidoun F, Torrejon N, Merjaneh Z, et al
    Studying the association between breast cancer and renal cell carcinoma.
    Breast Cancer Res Treat. 2021 Dec 2. pii: 10.1007/s10549-021-06465.
    PubMed         Abstract available

  22. BRANDS-APPELDOORN ATPM, Thomma RCM, Janssen L, Maaskant-Braat AJG, et al
    Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06461.
    PubMed         Abstract available


  23. TESCH ME, Speers C, Diocee RM, Gondara L, et al
    Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Cancer. 2021 Dec 2. doi: 10.1002/cncr.33982.
    PubMed         Abstract available

    Cancer Res

  24. CHOI SR, Hwang CY, Lee J, Cho KH, et al
    Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Cancer Res. 2021 Nov 29. pii: 0008-5472.CAN-21-0621.
    PubMed         Abstract available

    Clin Cancer Res

  25. MOORE HCF, Barlow WE, Somlo G, Gralow JR, et al
    A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3131.
    PubMed         Abstract available

  26. ZHANG J, Ji D, Cai L, Yao H, et al
    First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-2827.
    PubMed         Abstract available

    Eur J Cancer

  27. PATSOURIS A, Diop K, Tredan O, Nenciu D, et al
    Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    Eur J Cancer. 2021;159:283-295.
    PubMed         Abstract available

    Genes Chromosomes Cancer

  28. HAAN JC, Bhaskaran R, Ellappalayam A, Bijl Y, et al
    MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
    Genes Chromosomes Cancer. 2021 Nov 28. doi: 10.1002/gcc.23014.
    PubMed         Abstract available


  29. HODA RS, Bowman AS, Zehir A, Razavi P, et al
    Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 te
    Histopathology. 2021;78:498-507.
    PubMed         Abstract available

  30. GHOSSEIN CA, Khimraj A, Dogan S, Xu B, et al
    Metastasis to the thyroid gland: a single-institution 16-year experience.
    Histopathology. 2021;78:508-519.
    PubMed         Abstract available

  31. NOSKE A, Ammann JU, Wagner DC, Denkert C, et al
    A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Histopathology. 2021;78:567-577.
    PubMed         Abstract available

    J Natl Cancer Inst

  32. LAMBERTINI M, Boni L, Michelotti A, Magnolfi E, et al
    Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440062. doi: 10.1093.
    PubMed         Abstract available

    The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440063. doi: 10.1093.

    J Surg Oncol

  34. CHICHURA A, Hunt J, Lang J, Pederson H, et al
    Lapses in breast cancer screening for highly penetrant mutation carriers during pregnancy and lactation.
    J Surg Oncol. 2021 Dec 2. doi: 10.1002/jso.26761.
    PubMed         Abstract available

    Mod Pathol

  35. SUN X, Zhai J, Sun B, Parra ER, et al
    Effector memory cytotoxic CD3(+)/CD8(+)/CD45RO(+) T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
    Mod Pathol. 2021 Nov 27. pii: 10.1038/s41379-021-00973.
    PubMed         Abstract available

    NPJ Breast Cancer

  36. EL BAIRI K, Haynes HR, Blackley E, Fineberg S, et al
    The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
    NPJ Breast Cancer. 2021;7:150.
    PubMed         Abstract available

  37. WATT GP, Knight JA, Lin C, Lynch CF, et al
    Mammographic texture features associated with contralateral breast cancer in the WECARE Study.
    NPJ Breast Cancer. 2021;7:146.
    PubMed         Abstract available

  38. EKTEFAIE Y, Yuan W, Dillon DA, Lin NU, et al
    Integrative multiomics-histopathology analysis for breast cancer classification.
    NPJ Breast Cancer. 2021;7:147.
    PubMed         Abstract available

    Oncol Rep

  39. CHIU YJ, Tsai FJ, Bau DT, Chang LC, et al
    Nextgeneration sequencing analysis reveals that MTH3, a novel curcuminoid derivative, suppresses the invasion of MDAMB231 triplenegative breast adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed         Abstract available

    PLoS One

  40. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed         Abstract available

  41. ALACHRAM H, Chereda H, Beissbarth T, Wingender E, et al
    Text mining-based word representations for biomedical data analysis and protein-protein interaction networks in machine learning tasks.
    PLoS One. 2021;16:e0258623.
    PubMed         Abstract available

  42. SHAMMOUT ODA, Ashmawy NS, Shakartalla SB, Altaie AM, et al
    Comparative sphingolipidomic analysis reveals significant differences between doxorubicin-sensitive and -resistance MCF-7 cells.
    PLoS One. 2021;16:e0258363.
    PubMed         Abstract available

  43. KEETILE M, Ndlovu K, Letamo G, Disang M, et al
    Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana.
    PLoS One. 2021;16:e0255581.
    PubMed         Abstract available

  44. ADEYEMI OJ, Gill TL, Paul R, Huber LB, et al
    Evaluating the association of self-reported psychological distress and self-rated health on survival times among women with breast cancer in the U.S.
    PLoS One. 2021;16:e0260481.
    PubMed         Abstract available

  45. BRUCKMANN NM, Kirchner J, Morawitz J, Umutlu L, et al
    Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    PLoS One. 2021;16:e0260804.
    PubMed         Abstract available


  46. DEN DEKKER BM, Bakker MF, de Lange SV, Veldhuis WB, et al
    Reducing False-Positive Screening MRI Rate in Women with Extremely Dense Breasts Using Prediction Models Based on Data from the DENSE Trial.
    Radiology. 2021 Aug 17:210325. doi: 10.1148/radiol.2021210325.
    PubMed         Abstract available

  47. ONISHI N, Li W, Newitt DC, Harnish RJ, et al
    Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Radiology. 2021 Aug 24:203645. doi: 10.1148/radiol.2021203645.
    PubMed         Abstract available

  48. FAN M, Cui Y, You C, Liu L, et al
    Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study.
    Radiology. 2021 Nov 30:210738. doi: 10.1148/radiol.2021210738.
    PubMed         Abstract available

    Radiother Oncol

  49. KAO YS
    Comment to "long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost".
    Radiother Oncol. 2021 Nov 29. pii: S0167-8140(21)09012.

    Semin Oncol

  50. LIM J, Lee SA, Khil EK, Byeon SJ, et al
    COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature.
    Semin Oncol. 2021 Oct 26. pii: S0093-7754(21)00069.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.